INSIGHTS ON CLINICAL TRIAL PARTNERING

• Turning Patient Advocacy Into Meaningful Trial Engagement

  See how structured PAO engagement can inform protocol design, reduce participation barriers, and strengthen recruitment and retention.

• Biotech Delivers A Superior Patient And Site Experience

  To become the sponsor of choice for sites and patients in congenital hyperinsulinism clinical trials, a small biotech company prioritized delivering a superior experience while streamlining operations.

• TPDs: Developing The Next Generation Of Oral Therapeutics

  Targeted Protein Degraders are a revolutionary drug class with challenges in bioavailability and formulation complexity. Strategic CDMO partnerships are key to successful, scalable development.

• Considerations For Drug-Device Combination Products In Rare Diseases

  The development process for these products is complex, requiring careful consideration of regulatory requirements, technical feasibility, clinical efficacy, and patient-centered design.

• Transparent Pricing In Bioanalysis: A Feature, Not A Bonus

  3/9/2026

  Unclear CRO pricing leaves small biotechs vulnerable to budget swings. Transparent, itemized costs cut financial risk, sharpen planning, and build trust by setting expectations from the start.

• CRO Uses CRIO eSource To Double Monitoring Productivity

  1/31/2025

  Examine the transformative impact of eSource technology on monitoring productivity during a global Phase 3 trial conducted by a Contract Research Organization (CRO) amid the COVID-19 pandemic.

• Why Sponsors Are Moving Away From Multi-Vendor Trial Support

  7/13/2026

  Multi-vendor trial models often limit visibility and coordination. Discover how centralized operations can streamline workflows, control costs, and improve stakeholder experiences.

• Why Early Medical Assessment Matters In Clinical Trials

  1/6/2026

  Early medical assessment reduces risk, improves patient selection, and avoids trial delays. Learn how starting early boosts compliance, speeds timelines, and protects participants and results.

• Why Early CRO Choice Is Critical To Accelerating Delivery Of Your Clinical Program

  2/9/2026

  Regulatory readiness for global expansion begins in Phase I. A development partner should design your trial and data collection to anticipate downstream regulatory requirements in your target regions.